Approve of CEO. "The positive results from this study, coupled with the earlier reported positive results from the pivotal Phase 3 efficacy trial, enable our teams to finalize regulatory submissions seeking approval in the U.S., Europe and other key global markets," said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals. Biopharma CEO of Braeburn with a reputation for building high performing teams and strategies, and a passion for innovation. Ms. Sheldon has more than 25 years of experience leading pharmaceutical development and commercialization in the United States and globally. Close. Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn's Board of Directors. Braeburn Pharmaceuticals announced that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburnâs Board of Directors. PRINCETON, N.J., June 5, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn's Board of Directors. â USA, NJ â Braeburn Pharmaceuticals, Inc. (NASDAQ:BBRX), announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburnâs Board of Directors. A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of ⦠A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of ⦠Behshad Sheldon, who helped to found Braeburn in 2012, is slated to step down from Braeburn⦠⦠She currently also serves as the President and Chief Executive Officer of Braeburn Pharmaceuticals, Inc., or Braeburn, a portfolio company of ⦠A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of Global Central Nervous System (CNS) and Pain Therapeutic Areas for Teva [â¦] Other executives include Louis Ricigliano, Chief Financial Officer; Paul Johnson, Chief Commercial Officer. Braeburn Pharmaceuticals's President & CEO, Director is Mike Derkacz. Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. Braeburn Pharmaceuticals' President and CEO, Behshad Sheldon, was also selected as a bronze award winner in the category of "Best Female Executive of the Year." A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of Global Central Nervous System and Pain ⦠Mike Derkacz. I have been in the pharmaceutical/biotech field for nearly 20 years and Braeburn is head and shoulders above any of the other companies I have worked for. 24 Ratings. PRINCETON, N.J., June 5, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn's Board of Directors. Braeburn Pharmaceuticals Inc., a Princeton-based commercial stage pharmaceutical company, announced that Michael M. Derkacz has been named CEO ⦠Most recently, Derkacz worked as senior VP and head of global central nervous system and pain therapeutic areas for Teva Pharmaceuticals (NYSE:TEVA). Mike Derkacz is President/CEO at Braeburn Pharmaceuticals Inc. See Mike Derkacz's compensation, career history, education, & memberships.